Provide your patients with an opportunity for a lasting defence3
Tavlesse is the 1st and only targeted agent that helps prevent immune-mediated platelet destruction.4
Tavlesse®, the first spleen tyrosine kinase inhibitor indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments1,2
Stand strong against platelet destruction.
Tavlesse is the 1st and only targeted agent that helps prevent immune-mediated platelet destruction.4
Early onset of efficacy and robust improvements in platelet levels4
Median time to first response was 15 days in overall responders4
59% less bleeding vs placebo1, 2, 5
No serious or severe bleeding5
Less rescue medication required vs placebo4
59% did not require rescue medication at any visit5
Durable benefit5
Demonstrated improvements in platelet counts for up to 4 years5
Oral dosing with no food restrictions1,2
The convenience of an oral medication that can be taken with or without food1,2
Mild to moderate adverse reactions1,2
The majority of adverse reactions observed in clinical trials were mild or moderate. However, serious adverse reactions such as febrile neutropenia, hypertensive crisis or infections may occur4
ITP is a heterogeneous disease with a complex, multifactorial pathogenesis6
Tavlesse is indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments1,2
Indiction: Tavlesse is indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments.
ITP: immune thrombocytopenia
References: